Spectrum of BCR-ABL Kinase Domain Mutations in North Macedonia in Patients With CML Resistant to Imatinib

被引：0

作者：

Stojanovska-Jakimovska, Simona ^{[1
]}

Cvetanoski, Milche ^{[1
]}

Ridova, Nevenka ^{[1
]}

Trajkova, Sanja ^{[1
]}

Popova-Labachevska, Marija ^{[1
]}

Mojsovska, Tara ^{[1
]}

Dukovski, Dushko ^{[1
]}

Pivkova-Veljanovska, Aleksandra ^{[1
]}

Stojanovski, Zlate ^{[1
]}

Krstevska-Balkanov, Svetlana ^{[1
]}

Pavkovic, Marica ^{[1
]}

Chadievski, Lazar ^{[1
]}

Panovska-Stavridis, Irina ^{[1
]}

Ivanovski, Martin ^{[1
]}

Gjorgievska, Emilija ^{[2
]}

机构：

[1] Univ Ss Cyril & Methodius, Fac Med, Univ Clin Hematol Skopje, Clin Ctr Mother Teresa, Skopje, North Macedonia

[2] Ss Cyril & Methodius Univ, Fac Pharm, Skopje, North Macedonia

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

CML; resistance; mutation; TKI inhibitor; therapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-575

引用

页码：S375 / S375

页数：1

共 50 条

[1] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
Yuan Wei
Mats Hardling
Bob Olsson
Rahil Hezaveh
Anne Ricksten
Dick Stockelberg
Hans Wadenvik
Annals of Hematology, 2006, 85 : 841 - 847
[2] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
Wei, Yuan
Hardling, Mats
Olsson, Bob
Hezaveh, Rahil
Ricksten, Anne
Stockelberg, Dick
Wadenvik, Hans
ANNALS OF HEMATOLOGY, 2006, 85 (12) : 841 - 847
[3] The mutation spectrum of CML patients resistant to, imatinib: More heterogeneous than just BCR-ABL kinase domain point mutations?
Lundan, Tuija
Gruber, Franz
Silye, Aleksandra
Hjorth-Hansen, Henrik
Mikkola, Ingvild
Remes, Kari
Sirnonsson, Bengt
Gedde-Dahl, Tobias
Porkka, Kimano
BLOOD, 2007, 110 (11) : 579A - 579A
[4] Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib
Irving, JAE
O'Brien, S
Lennard, AL
Minto, L
Lin, F
Hall, AG
CLINICAL CHEMISTRY, 2004, 50 (07) : 1233 - 1237
[5] BCR-ABL KINASE DOMAIN MUTATION FREQUENCY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO IMATINIB THERAPY
Tikhonova, V.
Misyurina, E.
Kesaeva, L.
Finashutina, Y.
Krutov, A.
Aksenova, E.
Soldatova, I.
Soldatkina, O.
Ivanova, V.
Novitskaya, N.
Arshanskaya, E.
Lazarev, I.
Volkova, M.
Pospelova, T.
Konstantinova, T.
Vysotskaya, L.
Voloditcheva, E.
Lapin, V.
Davydkin, I.
Turkina, A.
Kolosheinova, T.
Goryacheva, S.
Chelysheva, E.
Pristupa, A.
Golubenko, R.
Gavrilova, L.
Volkova, S.
Kuchma, G.
Ovsyannikova, E.
Zaklyakova, L.
Kaplanov, K.
Klitochenko, T.
Misyurin, A.
HAEMATOLOGICA, 2013, 98 : 548 - 548
[6] BCR-ABL kinase domain mutations & SNPs in imatinib resistant or intolerant chronic myeloid leukaemia patients
O'Connor, Lisa M.
Langabeer, Stephen
McCann, Shaun R.
Conneally, Eibhlin
BLOOD, 2007, 110 (11) : 699A - 700A
[7] PREVALENCE OF BCR-ABL IMATINIB RESISTANT MUTATIONS IN PORTUGUESE CHRONIC MYELOID LEUKAEMIA (CML) PATIENTS
Palmeiro, A.
Torres, F.
Lemos, R.
Teixeira, M.
Gabriel, H.
Rendeiro, P.
Tavares, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 539 - 539
[8] BCR-ABL TYROSINE KINASE MUTATIONS IN IMATINIB MESYLATE RESISTANT CML PATIENTS FROM OMAN: SINGLE CENTRE EXPERIENCE
Pathare, V.
Alkindi, S.
Al Zadjali, A.
Al Farsi, S.
Huneini, N.
Zia, B.
Dennison, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 576 - 576
[9] Analysis of mutations in the BCR-ABL TK domain in CML patients
Nesslboeck, M.
Preuner, S.
Lion, T.
KLINISCHE PADIATRIE, 2010, 222 (03): : 217 - 217
[10] Characterization of the BCR-ABL kinase domain mutations in CML patients failing imanitib therapy
Kuo, F. C.
Kuo, C.
Sholl, L.
Longtine, J. A.
LABORATORY INVESTIGATION, 2007, 87 : 249A - 249A

← 1 2 3 4 5 →